Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

An Engineered Human Follistatin Variant: Insights into the Pharmacokinetic and Pharmocodynamic Relationships of a Novel Molecule with Broad Therapeutic Potential

Amita Datta-Mannan, Benjamin Yaden, Venkatesh Krishnan, Bryan E. Jones and Johnny E. Croy
Journal of Pharmacology and Experimental Therapeutics March 2013, 344 (3) 616-623; DOI: https://doi.org/10.1124/jpet.112.201491
Amita Datta-Mannan
Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Yaden
Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkatesh Krishnan
Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan E. Jones
Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johnny E. Croy
Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 344 no. 3 616-623
DOI 
https://doi.org/10.1124/jpet.112.201491
PubMed 
23249626

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received November 1, 2012
  • Accepted December 14, 2012
  • Published online February 19, 2013.

Article Versions

  • Earlier version (December 17, 2012 - 07:05).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Amita Datta-Mannan,
  2. Benjamin Yaden,
  3. Venkatesh Krishnan,
  4. Bryan E. Jones, and
  5. Johnny E. Croy
  1. Departments of Drug Disposition Development/Commercialization (A.D.-M.) Biotechnology Discovery Research (J.E.C.), and Musculoskeletal Research (B.Y., V.K.), Lilly Research Laboratories, Indianapolis, Indiana; Biotechnology Discovery Research (B.E.J.), Applied Molecular Evolution, San Diego, California; and Department of Biology, School of Science, Center for Regenerative Biology and Medicine, Indiana University–Purdue University, Indianapolis, Indiana (B.Y., V.K.)
  1. Address correspondence to:
    Benjamin Yaden, Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: yadenbc{at}lilly.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: December 2012 to December 2023

AbstractFullPdf
Dec 201292032
Jan 2013105074
Feb 2013419975
Mar 20133592448
Apr 2013112423
May 201382742
Jun 201337626
Jul 2013861242
Aug 2013521131
Sep 2013411134
Oct 2013561036
Nov 201332327
Dec 201340930
Jan 201427924
Feb 2014211027
Mar 2014592445
Apr 2014312124
May 2014262050
Jun 2014215825
Jul 2014253924
Aug 2014332410
Sep 2014193034
Oct 2014163022
Nov 2014182413
Dec 2014151912
Jan 2015162824
Feb 2015121313
Mar 2015282222
Apr 2015133122
May 2015162920
Jun 2015184729
Jul 2015324534
Aug 201511314
Sep 2015102915
Oct 2015143322
Nov 2015233020
Dec 2015192513
Jan 2016263223
Feb 201683114
Mar 2016282232
Apr 2016132325
May 2016211018
Jun 2016212017
Jul 2016142514
Aug 2016272819
Sep 2016183120
Oct 201683230
Nov 201664310
Dec 201623111
Jan 201723512
Feb 201733914
Mar 201714514
Apr 201732811
May 20173229
Jun 201701711
Jul 20170141
Aug 20171157
Sep 201713119
Oct 20173217
Nov 201753618
Dec 201712015
Jan 201833012
Feb 201833321
Mar 201832315
Apr 201812528
May 201873441
Jun 201822417
Jul 201842622
Aug 201862928
Sep 20180259
Oct 201823225
Nov 201803019
Dec 201824117
Jan 20194654
Feb 20193627
Mar 20193979
Apr 20193247
May 20194379
Jun 20191863
Jul 20193556
Aug 20191233
Sep 20192534
Oct 20196136
Nov 20195531
Dec 20192432
Jan 20204825
Feb 20202435
Mar 20202054
Apr 20202333
May 2020900
Jun 20201929
Jul 20201802
Aug 20201223
Sep 20201702
Oct 20201812
Nov 20201402
Dec 20202202
Jan 20212277
Feb 20212883
Mar 202124992
Apr 20213833
May 20213868
Jun 20212161
Jul 2021734
Aug 20212045
Sep 20211730
Oct 20211832
Nov 20213015
Dec 20213244
Jan 202219210
Feb 20221052
Mar 20221111
Apr 20222835
May 20221424
Jun 20222022
Jul 20222523
Aug 20221726
Sep 20222753
Oct 20222065
Nov 20222412
Dec 20221813
Jan 20231452
Feb 20231631
Mar 20231617
Apr 20231210
May 20232536
Jun 20232841
Jul 20231510
Aug 20231476
Sep 20231830
Oct 20232645
Nov 202330115
Dec 20231912

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 344 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 344, Issue 3
1 Mar 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An Engineered Human Follistatin Variant: Insights into the Pharmacokinetic and Pharmocodynamic Relationships of a Novel Molecule with Broad Therapeutic Potential
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

PK and PD of Novel Engineered Follistatin

Amita Datta-Mannan, Benjamin Yaden, Venkatesh Krishnan, Bryan E. Jones and Johnny E. Croy
Journal of Pharmacology and Experimental Therapeutics March 1, 2013, 344 (3) 616-623; DOI: https://doi.org/10.1124/jpet.112.201491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

PK and PD of Novel Engineered Follistatin

Amita Datta-Mannan, Benjamin Yaden, Venkatesh Krishnan, Bryan E. Jones and Johnny E. Croy
Journal of Pharmacology and Experimental Therapeutics March 1, 2013, 344 (3) 616-623; DOI: https://doi.org/10.1124/jpet.112.201491
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TRPA1 inhibitors ameliorate tear gas-induced skin injuries
  • Treatment of SM Corneal Injury by Augmenting the DDR
  • Symptomatic reversal of botulism by aminopyridines
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics